A5069604861- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Ubiquitin and proteasome pathways
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- HER2/EGFR in Cancer Research
- Synthesis and Biological Activity
PharmaMar (Spain)
2022-2024
This open-label, two-part, phase Ib drug–drug interaction study investigated whether the pharmacokinetic (PK) and safety profiles of lurbinectedin (LRB), a marine-derived drug, are affected by co-administration itraconazole (ITZ), strong CYP3A4 inhibitor, in adult patients with advanced solid tumors. In Part A, three were sequentially assigned to Sequence 1 (LRB 0.8 mg/m2, 1-h intravenous [IV] + ITZ 200 mg/day oral Cycle [C1] LRB alone 3.2 h, IV 2 [C2]). B, 11 randomized (1:1) receive either...
This open-label, two-way, crossover, phase Ib drug–drug interaction study investigated whether the pharmacokinetics (PKs) and safety profile of lurbinectedin (LRB) are affected by co-administration a moderate CYP3A4 inducer (bosentan, BOS) in adult patients with advanced solid tumors. Eleven were randomly assigned to Sequence 1 (LRB + BOS Cycle [C1] LRB alone 2 [C2]) or C1 C2), finally, eight (four per sequence) considered evaluable for PK assessment. (3.2 mg/m2, h [h], intravenous) was...
Abstract Previous studies showed antitumor activity for plitidepsin plus dexamethasone (DXM) in relapsed/refractory multiple myeloma (r/r MM), and vitro synergism with bortezomib (BTZ) or DXM against MM cells. This phase I trial evaluated (3‐h intravenous infusion Day 1 15), BTZ (subcutaneous bolus 1, 4, 8, 11), (orally 15, 22), every 4 weeks 36 r/r patients. Twenty‐two patients were treated using a standard dose escalation design (10 at the recommended [RD] cohort), 14 additional to expand...